An alphavirus replicon particle delivering prefusion-stabilized spike protein provides potent immunoprotection against SARS-CoV-2 Omicron variant  

作　　者：Hong-Qing Zhang Ya-Nan Zhang Zhe-Rui Zhang Xiao-Ling Chen Yan-Yan Hu Yu-Jia Shi Jing Wang Cheng-lin Deng Bo Zhang Xiao-Dan Li Han-Qing Ye 

机构地区：[1]Key Laboratory of Special Pathogens and Biosafety,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan,China [2]University of Chinese Academy of Sciences,Beijing 100049,China [3]Hunan Normal University,School of Medicine,Changsha 410081,China

出　　处：《Signal Transduction and Targeted Therapy》2023年第1期6-9,共4页信号转导与靶向治疗（英文）

基　　金：supported by the National Key Research and Development Program of China(2018YFA0507201).

摘　　要：Dear Editor,The prolonged outbreak and spread of coronavirus disease 2019(COVID-19),caused by SARS-CoV-2 poses a great threat to global economic and public health.The protective efficacy of the vaccines based on the spike protein(S)of SARS-CoV-2 has been compromised by the emergence of variants of concern(VOC).

关 键 词：protective STABILIZED PARTICLE 

分 类 号：R373[医药卫生—病原生物学]